|1.||Hirshberg, Boaz: 15 articles (11/2015 - 11/2011)|
|2.||Frederich, Robert: 13 articles (08/2015 - 05/2010)|
|3.||Raz, Itamar: 9 articles (11/2015 - 10/2010)|
|4.||Bhatt, Deepak L: 8 articles (11/2015 - 11/2011)|
|5.||Scirica, Benjamin M: 8 articles (11/2015 - 11/2011)|
|6.||Chen, Roland: 8 articles (04/2012 - 05/2010)|
|7.||Mosenzon, Ofri: 7 articles (11/2015 - 10/2013)|
|8.||Iqbal, Nayyar: 7 articles (11/2014 - 10/2013)|
|9.||Braunwald, Eugene: 6 articles (08/2015 - 11/2011)|
|10.||Allen, Elsie: 6 articles (11/2014 - 04/2011)|
|1.||Type 2 Diabetes Mellitus (MODY)
10/22/2009 - "In well designed, 24-week trials in treatment-naive patients with type 2 diabetes mellitus, monotherapy with oral saxagliptin 2.5 or 5 mg once daily significantly improved glycaemic control, as measured by mean glycosylated haemoglobin (HbA(1c)) levels, relative to placebo. "
01/01/2013 - "To assess safety and efficacy of saxagliptin in older patients with type 2 diabetes mellitus (T2DM). "
01/01/2013 - "Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus."
01/01/2014 - "Pooled analyses were performed of 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add-on therapy in patients with type 2 diabetes mellitus (T2DM) as well as a subset of 11 saxagliptin + metformin studies. "
01/01/2014 - "Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials."
|2.||Hypoglycemia (Reactive Hypoglycemia)
11/01/2015 - "In clinical trials, saxagliptin significantly improved glycemic control when used as monotherapy or as add-on therapy to other antidiabetes agents and was associated with a low risk of hypoglycemia. "
05/01/2013 - "Saxagliptin improved glycemic measures, resulted in low rates of confirmed hypoglycemia, and was well tolerated in patients with or without CVD and CV risk factors."
11/01/2015 - "Saxagliptin demonstrated statistically significant and clinically meaningful improvements in glycemic control and a low risk of hypoglycemia in patients with T2DM. "
04/01/2012 - "Hypoglycemia was reported in 18.4% and 19.9% of patients in the saxagliptin and placebo groups, respectively (confirmed hypoglycemia: 5.3%, 3.3%). "
01/01/2012 - "Serious adverse events (AEs) and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed hypoglycemia was low across all treatment groups (saxagliptin-treated, 2 [0.7]; control, 1 [1.4]). "
|3.||Hypertension (High Blood Pressure)
10/01/2014 - "In patients with T2DM, saxagliptin 5 mg/d was similarly effective in improving glycemic control, with an AE profile similar to that of placebo, irrespective of CVD history, number of CV risk factors, hypertension, or statin use. "
08/15/2015 - "The inhibition of the renal DPP-4 activity induced by saxagliptin may contribute to ameliorating renal injury in hypertension-related renal injury. "
05/01/2013 - "Differences in adjusted mean change from baseline HbA1c (95% CI) were greater with saxagliptin compared with placebo in patients with a history of CVD (-0.64% [-0.90 to -0.38]) and no history of CVD (-0.68% [-0.78 to -0.58]); with ≥ 2 CV risk factors (-0.73% [-0.85 to -0.60]) and 0 to 1 CV risk factor (-0.62% [-0.75 to -0.48]); with statin use (-0.70% [-0.89 to -0.52]) and no statin use (-0.66% [-0.77 to -0.56]); and with hypertension (-0.69% [-0.82 to -0.57]) and no hypertension (-0.66% [-0.80 to -0.52]). "
01/01/2015 - "In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. "
01/01/2015 - "Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. "
11/01/2015 - "However, the analysis of the components of the secondary end point of the saxagliptin study showed an increased number of hospitalizations for heart failure (HF) in treated patients versus placebo. "
10/01/2015 - "In addition, at a median follow-up of 2.1 years in the large SAVOR-TIMI 53 study, with the exception of a 27 % greater risk of hospitalization for heart failure, the addition of saxagliptin to standard of care neither reduced nor increased the rate of ischemic cardiovascular events in at-risk patients. "
06/01/2015 - "The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. "
01/01/2015 - "A concern arose related to congestive heart failure in the SAVOR TIMI trial of saxagliptin. "
12/01/2014 - "The increased risk of heart failure hospitalizations related to treatment with the DPP-4 inhibitor saxagliptin observed in the SAVOR TIMI 53 trial, is likely not to be a chance effect, but rather a previously unrecognized side effect of this drug, as this risk was very consistently apparent across all subgroups of this large multicenter, prospective, randomized trial. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
01/01/2015 - "This review summarizes findings from recently published post hoc analyses of saxagliptin clinical trials that have been conducted in patients with and without a history of cardiovascular disease and in patients with and without various risk factors for cardiovascular disease. "
01/01/2015 - "Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease."
07/01/2013 - "The SAVOR-TIMI 53 patient population, with differing background diabetes control and anti-diabetic treatment, provides global representation of diabetic patients with established cardiovascular disease or at high risk for cardiovascular disease and is well-positioned to determine the effect of saxagliptin on cardiovascular events."
07/01/2013 - "A total of 16 496 diabetic patients from North America (31.9%), Western Europe (26.0%), Eastern Europe (17.3%), Latin America (16.4%) and Asia (8.3%), with either established cardiovascular disease (78.3%) or with ≥two additional cardiovascular risk factors (21.7%) were randomised to saxagliptin or placebo. "
10/01/2014 - "Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials."
|9.||2- (3- (4- ethoxybenzyl)- 4- chlorophenyl)- 6- hydroxymethyltetrahydro- 2H- pyran- 3,4,5- triol
|1.||Cardiac Resynchronization Therapy
|3.||Renal Dialysis (Hemodialysis)